Provaris Energy has embarked on a bold journey to become a market-leading provider of regional marine compressed hydrogen transportation solutions for the emerging hydrogen markets in Europe and Asia Pacific. In September 2022, the company took a major step forward when it signed a memorandum of understanding (MoU) with major French power supplier, Total Eren.
The scope of the agreement includes identifying opportunities to collaborate on importing compressed green hydrogen into Europe and Asia using Provaris’s novel H2Neo carriers. The move bolsters the company’s plan to ship – at scale, using compression – green hydrogen to key European industrial hubs and help achieve European decarbonisation goals.
Geopolitical instability and energy-security fears are accelerating hydrogen adoption, supported by an increase in policy support and incentives. This is expanding large-scale demand for low-carbon hydrogen and increasing the need for its efficient distribution and delivery to industrial users in a ready-to-use form.
The move into Europe comes as Provaris progresses environmental submissions for its green hydrogen project for operations in northern Australia, and advances its Tiwi H2 project from concept to detailed design, engineering and approval.
‘The MoU gives real credibility to Provaris Energy’s compressed green hydrogen transportation solution and may also lead to funding options that make it a reality.
The timing is perfect as the EU is introducing initiatives and investment to accelerate introducing green hydrogen into the energy mix, to improve energy reliability and push its zero-carbon agenda.
The increased credibility this MoU attaches to Provaris’s H2 transport solution is clearly very important. The next important step is likely to be a class approval from the American Bureau of Shipping, in the shape of an approval for construction for the H2Neo carrier.
It is hoped that this approval will be forthcoming before the end of 2022, which would allow Provaris to engage in detailed discussions with shipyards that will initially focus on constructability and price, with a view to first voyages in 2026. These are likely to coincide with the first green hydrogen volumes from the numerous planned clean energy plants seeking a scalable hydrogen transport solution.’
Speaking to Edison, Provaris Energy CEO, Martin Carolan, said the MoU was a ‘vital step forward’, giving ‘external credibility and validation to Provaris’s plans’.
‘Our discussions with Total Eren have identified a strong alignment on the commercial and technical benefits of compression for the storage and transport of hydrogen’, said the CEO. ‘We look forward to a closer relationship to facilitate and accelerate the delivery of the first fleet of H2Neo carriers.’
In October, the company made an EPBC referral to the Australian government to show ‘the Tiwi H2 project will be developed in a safe, sustainable and efficient manner, pursuing a minimal environmental and social impact’. Provaris maintains its position as a potential early mover in the export of green hydrogen from Australia and the government’s decision is expected by late November 2022. The Tiwi H2 project is proposing the development of a 100,000 tonne per annum export green hydrogen project to South-East Asian markets, and a timeline for first exports in 2027.
Read Edison’s latest update on Provaris.
Edison offers investor relations, consulting and research publication services to paying clients. In accordance with Section 17(b) of the US Securities Act of 1933, please note the following important disclosures relating to Edison and its client relationship with Provaris Energy (the “Company”).
Edison is engaged by the Company on a paid basis for investor relations services and this communication relates to those services. In connection with its investor relations engagement by the Company, Edison’s standard fees are $20,000 per month. Additional compensation may have accrued since the publication of this notice.
In addition, Edison is engaged by the Company to separately provide investment research coverage of its stock. In connection with its investment research coverage, Edison’s standard fees are £60,000 pa. Additional compensation may have accrued since the publication of this notice. No compensation relating to Edison’s investment research coverage is in any way contingent upon any positive opinions or conclusions in its research reports.
Edison’s investor relations services are independent of its research services, although Edison’s investor relations activities may utilize published Edison research as a source, among others, in connection with its activities. Edison’s investor relations and investment research personnel regularly, but separately, interact with the Company. All source materials relating to any investor relations materials of Edison should be considered to be directly attributable to information provided to Edison by the Company or the third-party sources noted in the communication. While third-party information used in the publication of Edison’s communications is typically compiled from publicly available sources that are believed to be accurate, complete and reliable, Edison does not guarantee the accuracy or completeness of information contained therein, and typically does not independently verify such information.
NOTE THAT ALL INVESTMENTS ARE SUBJECT TO INHERENT RISK AND ANY INVESTMENT IN THE COMPANY IS SUBJECT TO SIGNIFICANT RISKS THAT SHOULD BE ASSESSED BY ANY INVESTOR AND THEIR ADVISORS. PLEASE CLOSELY REVIEW THE COMPANY’S AVAILABLE PUBLIC DISCLOSURES, INCLUDING RISK FACTORS FOR SPECIFIC CONSIDERATION, WHICH ARE AVAILABLE THROUGH THE COMPANY’S INVESTOR RELATIONS WEBSITE, LINKED ABOVE.
This communication may include forward-looking statements that are subject to risks and uncertainties. Factors that could cause a company’s actual results and financial condition to differ from expectations include, without limitation: political uncertainty, changes in general economic conditions that adversely affect the level of demand for the company’s products or services, changes in international and domestic financial markets and in the competitive environment, and other factors relating to the foregoing. All forward-looking statements relating to this communication are qualified in their entirety by this cautionary statement.
Edison is neither a FINRA-registered broker-dealer nor an SEC-registered investment adviser and does not provide any investment advisory or banking services. Edison’s investment research reports are bona fide publications of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. Edison does not offer or provide personal advice and its research provided is for informational purposes only. No mention of a particular security in any Edison communication constitutes a solicitation or recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison’s policies on personal dealing and conflicts of interest.
United in its passion for helping women with cancer and specializing in the development of potentially first-in-class medicines, Context Therapeutics has embarked on a mission to develop treatments for patients with hormone-driven cancers.
Get access to the very latest content matched to your personal investment style.